Intravenous thrombolysis in patients on direct oral anticoagulants: A survey of NIH StrokeNet sites

• Published in: Journal of stroke and cerebrovascular diseases 2024-12, Vol.33 (12), p.108074, Article 108074
• Main Authors: Yaghi, Shadi, Adeoye, Opeolu M., Khatri, Pooja, Mistry, Eva A.
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Administration, Oral; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Clinical Decision-Making; Direct Oral Anticoagulant; DOAC; Factor Xa Inhibitors - administration & dosage; Factor Xa Inhibitors - adverse effects; Fibrinolytic Agents - administration & dosage; Fibrinolytic Agents - adverse effects; Health Care Surveys; Humans; Ischemic Stroke - diagnosis; Ischemic Stroke - drug therapy; Practice Patterns, Physicians; Risk Factors; Stroke; Thrombolysis; Thrombolytic Therapy - adverse effects; Time Factors; Time-to-Treatment; Treatment Outcome; United States
• ISSN: 1052-3057; 1532-8511; 1532-8511
• DOI: 10.1016/j.jstrokecerebrovasdis.2024.108074

Patients with suspected ischemic stroke and use of Direct Oral Anticoagulants (DOACs) within 48 h are excluded from thrombolysis. We aimed to determine practice patterns across institutions in the NIH StrokeNet, a network of hospitals to conduct NIH-funded stroke clinical trials, in the United States. A survey was sent electronically to all NIH StrokeNet regional coordinating centers. The survey questions were geared towards understanding practice patterns with intravenous thrombolysis use in patients on DOACs. We reported proportions and percentages answers to the questions. We compared the likelihood of thrombolysis use in patients with recent DOAC ingestion (never vs. all other responses) across characteristics of survey responder using Chi Square. A total of 83 site principal investigators completed the survey; 78.3 % would never give thrombolysis to an otherwise eligible patients within 12-24 h from last DOAC ingestion and 54.2 % would never give thrombolysis to an otherwise eligible patient within 24-48 h from last DOAC ingestion. A higher proportion of vascular neurologists would never give thrombolysis in patients with DOAC ingestion within 12-48 h compared to other subspecialties (60.7 % vs. 36.4 %, p = 0.05). Nearly, 80 % would change their practice if a well-designed prospective study demonstrated that the symptomatic intracranial hemorrhage rate is not >5 %. A well-designed prospective study with a set safety threshold is likely to change practice patterns in giving thrombolysis in patients with recent DOAC ingestion, particularly among vascular neurologists who are more likely to never give thrombolysis in this setting.